Efficacy and Safety of Benralizumab in EGPA compared to mepolizumab.

Trial Identifier: D3253C00001
Sponsor: AstraZeneca
Start Date: October 2019
Primary Completion Date: August 2023
Study Completion Date: March 2026

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

No documents have been posted yet.

Trial Locations

Country Location
BE Brussel, BE, 1090
BE Brussels, BE, 1070
CA, AB Calgary, AB, CA, T2N 4Z6
CA, ON Hamilton, ON, CA, L8N 4A6
CA, ON Toronto, ON, CA, M5T 3A9
CA, ON Toronto, ON, CA, M5G 1E2
DE Bamberg, DE, 96049
DE Freiburg, DE, 79106
DE Hamburg, DE, 20251
DE Kirchheim, DE, 73230
DE Lübeck, DE, 23538
FR Dijon Cedex, FR, 21079
FR Marseille, FR, 13915
FR Montpellier, FR, 34090
FR Nantes Cedex 1, FR, 44093
FR Paris, FR, 75877
FR PARIS, FR, 75014
FR SURESNES CEDEX, FR, 92151
FR Toulouse, FR, 31059
GB Cambridge, GB, CB2 0QQ
GB Leicester, GB, LE3 9QP
GB London, GB, SE19RT
GB Portsmouth, GB, PO6 3LY
IL Ashkelon, IL, 7830604
IL Beer Sheva, IL, 84101
IL Jerusalem, IL, 91120
IL Ramat Gan, IL, 52621
IL Rehovot, IL, 7661041
IL Tel Aviv, IL, 6423906
IT Cuneo, IT, 12100
IT Firenze, IT, 50141
IT Milano, IT, 20132
IT MILANO, IT, 20162
IT NAPOLI, IT, 80131
IT Roma, IT, 00168
IT Torino, IT, 10128
JP Chiba-shi, JP, 260-0877
JP Kita-gun, JP, 761-0793
JP Sagamihara-shi, JP, 228-0815
JP Sendai-shi, JP, 980-8574
JP Shinjuku-ku, JP, 162-8666
US, CO Denver, CO, US, 80206
US, MI Ann Arbor, MI, US, 48109
US, MN Rochester, MN, US, 55905-0001
US, NM Albuquerque, NM, US, 87106
US, NY Great Neck, NY, US, 11021
US, NY New York, NY, US, 10021
US, PA Philadelphia, PA, US, 19104
US, TX Denison, TX, US, 75020
US, WA Seattle, WA, US, 98115